February 20, 2019

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Bardia et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d78dca5f9a1dad534907e8 — DOI: https://doi.org/10.1056/nejmoa1814213

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Clinical and pharmacogenetic factors associated with irinotecan toxicity· 2008 · 96 citations
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer· 2010 · 88 citations
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma· 2017 · 88 citations
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer· 2012 · 3,753 citations
The epidemiology of triple-negative breast cancer, including race

Authors

Aditya Bardia

Ingrid A. Mayer

Linda T. Vahdat

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

Cornell University

Yale University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion